Zhejiang Xianju Pharmaceutical Co., Ltd., a large-scale family planning drug enterprise in China, has a series of anti-early pregnancy drugs with post-dinuo (mifepristone)/bead-containing stop series, and is a listed enterprise focusing on the development/production and sales of steroid APIs and preparations
Zhejiang Xianju Pharmaceutical Co., Ltd. (stock code: 002332), formerly known as Xianju Pharmaceutical Factory, was founded in 1972 and is the largest and most complete steroid drug manufacturer in China. The company has a total share capital of 610,808,111 yuan, covers an area of 650 acres, and has more than 3,900 employees, including 15% of technical personnel and 35% of sales personnel.
The company's products are unique, and its main business is the development, production and sales of steroid APIs and preparations. It mainly produces three categories: corticosteroid drugs, sex hormone drugs (gynecological and family planning drugs) and anesthesia and muscle relaxant drugs. There are nearly 200 varieties in total, with a production capacity of 300 tons of APIs, 10 billion tablets, 500 million capsules, 500 million water injections, 20 million lyophilized powder injections, 35 million creams, and 60 million bags of granules.
At present, all of the company's products have passed the national GMP certification. 13 products, including vecuronium bromide, prednisone acetate, prednisolone, medroxyprogesterone acetate, etc., have been certified by the US FDA; 9 products, including cyproterone acetate, prednisolone, and norethindrone, have obtained the EU CEP certificate; Prednisolone, betamethasone dipropionate, and betamethasone valerate have passed the KFDA certification in South Korea; The small-volume injection production line and the integrated solid dosage production line (1) have passed the Colombian INVIMA certification.
The company has established long-term cooperative relations with more than 20 well-known domestic scientific research institutes (schools) such as Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Zhejiang University, China Pharmaceutical University, etc., and invested in the establishment of Zhejiang Xianju Pharmaceutical Technology Development Company. In recent years, it has successfully developed more than 30 new high-tech drugs and achieved nearly 30 scientific research achievements at or above the provincial level. Pidotimod original drug and granules, mometasone furoate and cream, tiotropium bromide and powder aerosol, ciclesonide and aerosol, rocuronium bromide and injection were included in the National Torch Program; Ropivacaine mesylate, levonorgestrel enteric-coated capsules, and methylprednisolone were included in the national key new product plan; The clinical research of the new anti-relapse drug thienorephine has been included in the national major new drug creation special project. The anti-early pregnancy drug "Hanzhu Stop" and the muscle relaxant drug "Xianlin" are famous brand products in Zhejiang. Recently, the company has won the top 10 export-oriented brands of China's APIs and the top 100 chemical and pharmaceutical brands in China.
The company has 13 wholly-owned and holding subsidiaries including Taizhou Xianju Pharmaceutical Co., Ltd. In order to achieve large-scale operation, the company plans to acquire land in Zhejiang Chemical Raw Material Base (Linhai Block) and Xianju Modern Industrial Park respectively as a new production base for APIs and preparations.
Xianju Pharmaceutical advocates a culture of truth, win-win and innovation, and adheres to the core values of "integrity, hard work, responsibility and win-win". The company adheres to the strategic concept of achieving a win-win situation in customers, enterprises, employees, and society, and advocates the value concept that personal value is reflected in the process of realizing enterprise value and social value. In the future development process, the company will continue to improve the management level of the enterprise, continue to develop high-tech products, give full play to the scale effect, expand the business field, and realize the take-off of the enterprise again.
